Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain

References

• Aymard C, Katz R T, Lafitte C, et al. Presynaptic inhibition and homosynaptic depression: a comparison between lower and upper limbs in normal subjects and patients with hemiplegia. Brain 2000; 123(Pt8)1668–702
   Google Scholar
• Stempien L, Tsai T. Intrathecal baclofen pump use for spasticity: a clinical survey. Am J Phys Med Rehabil 2000; 79: 536–41
   PubMed Web of Science ®Google Scholar
• Bowery N G, Bettler B, Froestl W, et al. Mammalian gamma-aminobutyric acid (B) receptors: structure and function. Pharmacol. Rev 2002; 54: 247–64
   PubMed Web of Science ®Google Scholar
• Price G W, Wilkin G P, Turnbull M J, Bowery N G. Are baclofen-sensitive GABAB receptors present on primary afferent terminals of the spinal cord?. Nature 1984; 307(5946)71–74
   PubMedGoogle Scholar
• Kaupmann K, Schuler V, Mosbacher J, et al. Human γ-aminobutyric acid type B receptors are differentially expressed and regulate inwardly rectifying K+ channels. PNAS 1998; 95: 14991–6
   PubMed Web of Science ®Google Scholar
• Li Y, Li X, Harvey P J, Bennett D J. Effects of baclofen on spinal reflexes and persistent inward currents in motor neurones of chronic spinal rats with spasticity. J Neurophysiol 2004; 92: 2694–703
   PubMed Web of Science ®Google Scholar
• Albright A L, Barry M J, Shafton D H, Ferson S S. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol 2001; 43(10)652–7
   PubMed Web of Science ®Google Scholar
• Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540–2
   PubMedGoogle Scholar
• Penn R D, Savoy S M, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989; 320: 1517–21
   PubMed Web of Science ®Google Scholar
• Smail B D, Peskine A, Roche N, Mailhan L, Thiebaut J-B, Bussel B. Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. Multiple Sclerosis 2006; 12: 101–3
   PubMed Web of Science ®Google Scholar
• Francisco G E, Latorre J M, Ivanhoe C B. Intrathecal baclofen therapy for spastic hypertonia in chronic traumatic brain injury. Brain Inj 2007; 21: 335–8
   PubMed Web of Science ®Google Scholar
• Becker R, Benes L, Sure U, Hellwig D, Bertalanffy H. Intrathecal baclofen alleviates autonomic dysfunction in severe brain injury. J Clin Neurosci 2000; 7: 316–19
   PubMed Web of Science ®Google Scholar
• Barry M J, VanSwearingen J M, Albright A L. Reliability and responsiveness of the Barry–Albright Dystonia Scale. Dev Med Child Neurol 1999; 41(6)404–11
   PubMed Web of Science ®Google Scholar
• Van Hilten B J, van de Beek W JT, Hoff J I, et al. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med 2000; 343(9)625–30
   PubMedGoogle Scholar
• Lind G, Schechtmann G, Winter J, et al. Drug-enhanced spinal stimulation for pain: a new strategy. Acta Neurochirurgica 2007; 97(Pt 1, Suppl.)57–63
   Google Scholar
• Godwin D A, Kim N-H†, Zuniga R. Stability of a baclofen and clonidine hydrochloride admixture for intrathecal administration. Hosp Pharm 2001; 36: 950–4
   Google Scholar
• Albright A L, Ferson S S. Intrathecal baclofen therapy in children. Neurosurg Focus 2006; 21(2)E3
   Google Scholar
• Albright A L, Cervi A, Singletary J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA 1991; 265: 1418–22
   PubMed Web of Science ®Google Scholar
• Albright A L, Shultz B. Plasma baclofen levels in children receiving continuous intrathecal baclofen infusion. J Child Neurol 1999; 14(6)408–9
   PubMedGoogle Scholar
• Ford B, Greene P, Louis E D, et al. Use of intrathecal baclofen in the treatment of patients with dystonia. Arch Neurol 1996; 53: 1241–6
   PubMedGoogle Scholar
• Patrick E, Ada L. The Tardieu Scale differentiates contracture from spasticity whereas the Ashworth Scale is confounded by it. Clin Rehab 2006; 20: 173–82
   PubMed Web of Science ®Google Scholar
• Plassat R, Perrouin Verbe B, et al. Treatment of spasticity with intrathecal Baclofen administration: long-term follow-up, review of 40 patients. Spinal Cord 2004; 42(12)686–93
   PubMed Web of Science ®Google Scholar
• Pandyan A D, Johnson G R, Price C IM, Curless R H, Barnes M P, Rodgers H. A review of the properties and limitations of the Ashworth and modified Ashworth scales as measures of spasticity. Clin Rehab 1999; 13(5)373–83
   PubMed Web of Science ®Google Scholar
• Rymer W Z, Katz R T. Spastic hypertonia: mechanisms and measurement. Arch Phys Med Rehabil 1989; 70: 144–55
   PubMedGoogle Scholar
• Biering-Sorensen F, Nielsen J B, Klinge K. Spasticity-assessment: a review. Spinal Cord 2006; 44(12)708–22
   PubMed Web of Science ®Google Scholar
• Pohl M, Rockstroh G, Rückriem S, et al. Measurement of the effect of a bolus dose of intrathecal baclofen by continuous measurement of force under fibreglass casts. Neurol 2002; 249: 1254–62
   Google Scholar
• Kroin J S, Ali A, York M, Penn R D. The distribution of medication along the spinal canal after chronic intrathecal administration. Neurosurgery 1993; 33: 226–30
   PubMedGoogle Scholar
• Vender J R, Hester S, Waller J L, Rekito A, Lee M R. Identification and management of intrathecal baclofen pump complications: a comparison of paediatric and adult patients. J Neurosurgery 2006; 104(S1)9–15
   PubMedGoogle Scholar
• Grabb P A, Guin-Renfroe S, Meythaler J M. Midthoracic catheter tip placement for intrathecal baclofen administration in children with quadriparetic spasticity. Neurosurgery 1999; 45: 833–7
   PubMed Web of Science ®Google Scholar
• Gooch J L, Oberg W A, Grams B, Ward L A, Walker M L. Complications of intrathecal baclofen pumps in children. Pediatr Neurosurg 2003; 39: 1–6
   PubMed Web of Science ®Google Scholar
• Bernards C M. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology 2006; 105: 169–78
   PubMed Web of Science ®Google Scholar
• Albright A L, Thompson K, Carlos S, Minnigh M B. Cerebrospinal fluid baclofen concentrations in patients undergoing continuous intrathecal baclofen therapy. Dev Med Child Neurol 2007; 49(6)423–5
   PubMedGoogle Scholar
• Cooper J A, Ridley B. Response of intrathecal baclofen resistance to dose reduction. Neurology 2006; 67: 1495–6
   PubMedGoogle Scholar
• Lagarce F, Faisant N, Desfontis J C, et al. Baclofen-loaded microspheres in gel suspensions for intrathecal drug delivery: in vitro and in vivo evaluation. Eur J Pharm Biopharm 2005; 61(3)171–80
   PubMed Web of Science ®Google Scholar
• Cruikshank M, Eunson P. Intravenous diazepam infusion in the management of planned intrathecal baclofen withdrawal. Dev Med Child Neurol 2007; 49(8)626–8
   PubMedGoogle Scholar
• Motta F, Buonaguro V, Stignani C. The use of intrathecal baclofen pump implants in children and adolescents: safety and complications in 200 consecutive cases. J Neurosurg 2007; 107(S1)32–35
   PubMedGoogle Scholar
• Pohl M, Rockstroh G, Ruckriem S, et al. Time course of the effect of a bolus dose of intrathecal baclofen on severe cerebral spasticity. J Neurol 2003; 250: 1195–2000
   PubMed Web of Science ®Google Scholar
• Yaksh T L, Hassenbusch S, Burchiel K. Inflammatory masses associated with intrathecal drug infusion: a review of preclinical evidence and human data. Pain Med 2002; 3: 300–12
   PubMed Web of Science ®Google Scholar
• North R B, Cutchis P N, Epstein J A. Spinal cord compression complicating subarachnoid infusion of morphine: case report and laboratory experience. Neurosurgery 1991; 29: 778–84
   PubMed Web of Science ®Google Scholar
• Ghorbel M T, Becker K G, Henley J M. Profile of changes in gene expression in cultured hippocampal neurons evoked by the GABAB receptor agonist baclofen. Physiol Genomics 2005; 22: 93–98
   PubMedGoogle Scholar